Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9 billion acquisition of French cancer firm Advanced Accelerator Applications.
Global efforts to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2017, released by WHO today.
An exploratory study has identified a link between gut bacteria and post-traumatic stress disorder that could bring us closer to fathoming the mechanisms of the complex condition.
CVS Health Corp.’s bid for Aetna Inc., which could be valued at more than $66 billion, would — if successful — combine two businesses that have traditionally been separate, health insurance and pharmacy-benefit management.
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
According to a new study from scientists at The Scripps Research Institute (TSRI), the common practice of growing influenza vaccine components in chicken eggs disrupts the major antibody target site on the virus surface, rendering the flu vaccine less effective in humans.
Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
US vascular surgeon John Martin found cancerous cells in his own neck while testing a portable ultrasound device called Butterfly iQ.
Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.